Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LQ087
- Development stage
- Preclinical
- Lead developer
- Novamab Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
LQ087 is a preclinical-stage bispecific VHH nanobody developed by Novamab for the treatment of inflammatory bowel disease (IBD) and psoriasis. It is uniquely designed for oral administration, aiming to provide localized therapeutic action within the gastrointestinal tract while improving patient compliance compared to injectable biologics. The molecule simultaneously targets and inhibits two key pro-inflammatory cytokines: tumor necrosis factor-like ligand 1A (TL1A) and the p19 subunit of interleukin-23 (IL-23p19). By blocking these synergistic pathways, LQ087 is intended to offer enhanced anti-inflammatory efficacy for chronic autoimmune conditions.
- Other names
- LQ087-Novamab-TL1A-IL-23p19-bispecific VHH nanobody-oral-IBD-PsoriasisLQ-087-Novamab-TL1A-IL-23p19-bispecific VHH nanobody-oral-IBD-PsoriasisLQ 087-Novamab-TL1A-IL-23p19-bispecific VHH nanobody-oral-IBD-Psoriasis
02
Targets
IL23A (Interleukin-23 p19 Subunit)TL1A (TNF-like cytokine 1A)
Beyond the preview
Go deeper on LQ087.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LQ087.